2026-10-25
Coherent clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,946 −5.25%
S&P 7,428 −3.39%
GOLD $4,132 +1.46%
BTC $75,633 −5.94%
VIX 23.84 +43.53%
latest tape · as of 18:03 UTC
The Screen · Technology · Scientific & Technical Instruments
Coherent Corp.
COHR · a US exchange · USD · Market cap $46.7B · 30,216 employees
Coherent Corp.
Not yet scored195.09 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 18:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price195.09 USD at the 4 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 4 Nov 2026
- Our regime readDistribution, as of 4 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 1.54)
- Last reviewed4 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $271.21 to $414.98, base estimate $390.81 (screen dated 2026-11-04).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning political buying, disclosed 2026-09-25
- Options put/call open interest 1.54, read 2026-11-05
- Ethical screen not yet scored
Price195.09 USD
Fair value390.81
Ethical score87.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-21Read Distribution250.60-22.2% to today ✓Markup gives way to Distribution after a 34% slide in 16 weeks
2026-07-02Read Markup376.99-48.3% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Coherent Corp. holds its Distribution at $195.09. The statistical read favours the buyers, held for 193 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 193 days |
| Price at the screen | $195.09 |
| Valuation | 57.58 trailing · 17.06 forward price to earnings |
| Values screen | Not scored · score 87.0 |
| Beta | 2.11 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 26.11% | Below 33% | Interest-bearing debt is just 26.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 12.56% | Below 49% | Money owed to the company is 12.6% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Coherent clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Coherent clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 47% discount to our $390.81 fair value, narrow competitive moat, 33.70% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 50.1% discount to the base estimate.
Third-party analyst targets: 25 covering, consensus Buy. The average target sits +115% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $390.81, with a range of $271.21 to $414.98, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it stands out
A 34%-growth business trading at just 17.1x forward earnings, with a narrow competitive moat and minimal debt. That is a 47% discount to our $390.81 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 25 analysts rate it Buy with a $420.00 average target, about 115% above the screened price.
| Forward P/E | 17.1xcheap for a company growing this fast |
| Trailing P/E | 57.6xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 4.12 |
| EPS, forward | 13.91 |
| Revenue growth | +33.7%strong top-line growth |
| Profit margin | 11.3%thin but positive margins |
| Return on equity | 8.0%a modest return on shareholder capital |
| FCF yield | -1.39% |
| Debt to equity | 0.32minimal debt: a conservative balance sheet |
| Current ratio | 2.43comfortably covers its short-term bills |
| Beta | 2.11much more volatile than the market |
| Short interest, float | 0.05% |
| 52-week range | 123.75 - 440.00 |
| Moat | NARROW |
| Market cap | $46.7B |
| Employees | 30,216 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCOHR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-04
Distribution $207.49
-1.3% Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Distribution $210.32
+0.0% Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Distribution $210.32
+0.0% Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Distribution $210.32
-11.3% Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Distribution $237.22
+0.0% Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Distribution $237.22
+13.3% Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 13.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Distribution $209.29
-16.5% Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 16.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Distribution $250.60
+0.0% Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Distribution · changed $250.60
-19.8% Entry 8
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 19.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 21% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381.
2026-10-14
Markup $312.62
+5.7% Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 91% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 338%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (21 analysts) rates it buy, with a mean price target of $381.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Marvell Sinks 14% in a Week on Lumentum Talks: Chipmakers Like It “Don’t Have a Choice” Yahoo Finance · 5d ago
- What Did It Take To Hold Novanta Stock? Yahoo Finance · 5d ago
- Coherent Stock Fell 11% as Intel and Amazon Earnings Hit AI Hardware Stocks. Here’s Where the Stock Could Go Yahoo Finance · 5d ago
- Applied Optoelectronics Plunges 15%, Coherent Tumbles 13% as Hyperscaler Spending Fears Hit AI Optics Stocks; Lumentum and Marvell Sink 10% Yahoo Finance · 6d ago
- Lumentum Jumps, Fades On Marvell Buyout Report Yahoo Finance · 7d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
GRMNGarmin
KEYSKeysight Technologies
TDYTeledyne Technologies
FTVFortive
TRMBTrimble Inc.
MKSIMKS Inc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-12 | LUTHER SHERRI R | Chief Financial Officer | 2,000 | $745,920 | |
| 2026-05-11 | XIA HOWARD H | Director | 2,000 | $709,000 | |
| 2026-05-11 | XIA HOWARD H | Director | 2,000 | $43,340 | |
| 2026-04-22 | LUTHER SHERRI R | Chief Financial Officer | 2,000 | $702,000 | |
| 2026-03-17 | XIA HOWARD H | Director | 4,240 | $1,040,943 | |
| 2026-03-17 | XIA HOWARD H | Director | 4,240 | $91,881 | |
| 2026-03-10 | ENG JULIE SHERIDAN | Chief Technology Officer | 1,454 | $375,394 | |
| 2026-03-09 | SKAGGS STEPHEN ANDREW | Director | 3,523 | $856,550 | |
| 2026-03-06 | DIGIROLOMO ENRICO | Director | 3,911 | $944,506 | |
| 2026-03-06 | DIGIROLOMO ENRICO | Director | 1,005 | $236,899 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $379.69 | -5.4% | · | $946 | -5.4% |
| 2 months | $307.50 | +16.8% | · | $1,168 | +16.8% |
| 3 months | $241.27 | +48.9% | · | $1,489 | +48.9% |
| 6 months | $198.50 | +81.0% | · | $1,810 | +81.0% |
| 1 year | $82.02 | +338.1% | · | $4,381 | +338.1% |
| 2 years | $66.62 | +439.3% | · | $5,393 | +439.3% |
| 3 years | $38.91 | +823.4% | · | $9,234 | +823.4% |
| 5 years | $70.10 | +412.6% | · | $5,126 | +412.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever COHR does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.